Citadel Advisors LLC reduced its position in ChemoCentryx, Inc. (NASDAQ:CCXI) by 48.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 12,508 shares of the biopharmaceutical company’s stock after selling 11,580 shares during the quarter. Citadel Advisors LLC’s holdings in ChemoCentryx were worth $117,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in CCXI. Teachers Advisors LLC increased its stake in ChemoCentryx by 8.4% in the 4th quarter. Teachers Advisors LLC now owns 40,288 shares of the biopharmaceutical company’s stock valued at $298,000 after buying an additional 3,114 shares during the period. Russell Investments Group Ltd. increased its stake in ChemoCentryx by 51.5% in the 1st quarter. Russell Investments Group Ltd. now owns 94,165 shares of the biopharmaceutical company’s stock valued at $686,000 after buying an additional 31,997 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in ChemoCentryx in the 1st quarter valued at $189,000. TIAA CREF Investment Management LLC increased its stake in ChemoCentryx by 37.5% in the 1st quarter. TIAA CREF Investment Management LLC now owns 128,546 shares of the biopharmaceutical company’s stock valued at $936,000 after buying an additional 35,049 shares during the period. Finally, Thrivent Financial For Lutherans acquired a new position in ChemoCentryx in the 1st quarter valued at $852,000. 50.12% of the stock is currently owned by institutional investors.

CCXI has been the topic of several recent research reports. BidaskClub cut shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research raised shares of ChemoCentryx from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Finally, Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research note on Tuesday, August 8th.

ChemoCentryx, Inc. (NASDAQ:CCXI) opened at 7.89 on Monday. The firm’s market capitalization is $384.29 million. ChemoCentryx, Inc. has a 52 week low of $5.19 and a 52 week high of $10.80. The firm has a 50-day moving average of $7.45 and a 200 day moving average of $7.83.

ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The business had revenue of $8.94 million during the quarter. Analysts predict that ChemoCentryx, Inc. will post ($0.90) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Citadel Advisors LLC Sells 11,580 Shares of ChemoCentryx, Inc. (CCXI)” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/citadel-advisors-llc-sells-11580-shares-of-chemocentryx-inc-ccxi/1634190.html.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.